535 related articles for article (PubMed ID: 33986872)
1. Triple-negative breast cancer: A run-through of features, classification and current therapies.
Manjunath M; Choudhary B
Oncol Lett; 2021 Jul; 22(1):512. PubMed ID: 33986872
[TBL] [Abstract][Full Text] [Related]
2. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
[TBL] [Abstract][Full Text] [Related]
3. Triple-negative breast cancer: advancements in characterization and treatment approach.
Hurvitz S; Mead M
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the molecular subtypes of triple-negative breast cancer among non-Asian and Taiwanese women.
Tseng LM; Chiu JH; Liu CY; Tsai YF; Wang YL; Yang CW; Shyr YM
Breast Cancer Res Treat; 2017 Jun; 163(2):241-254. PubMed ID: 28299476
[TBL] [Abstract][Full Text] [Related]
5. Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.
Luo C; Wang P; He S; Zhu J; Shi Y; Wang J
Front Oncol; 2022; 12():919072. PubMed ID: 35795050
[TBL] [Abstract][Full Text] [Related]
6. Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies.
Gupta GK; Collier AL; Lee D; Hoefer RA; Zheleva V; Siewertsz van Reesema LL; Tang-Tan AM; Guye ML; Chang DZ; Winston JS; Samli B; Jansen RJ; Petricoin EF; Goetz MP; Bear HD; Tang AH
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32846967
[TBL] [Abstract][Full Text] [Related]
7. Targeted Therapies in Triple-Negative Breast Cancer.
Marmé F; Schneeweiss A
Breast Care (Basel); 2015 Jul; 10(3):159-66. PubMed ID: 26557820
[TBL] [Abstract][Full Text] [Related]
8. Targeted Therapeutic Strategies for Triple-Negative Breast Cancer.
Li Y; Zhan Z; Yin X; Fu S; Deng X
Front Oncol; 2021; 11():731535. PubMed ID: 34778045
[TBL] [Abstract][Full Text] [Related]
9. Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies.
Khosravi-Shahi P; Cabezón-Gutiérrez L; Custodio-Cabello S
Asia Pac J Clin Oncol; 2018 Feb; 14(1):32-39. PubMed ID: 28815913
[TBL] [Abstract][Full Text] [Related]
10. Research Progress on Molecular Subtyping and Modern Treatment of Triple-Negative Breast Cancer.
Tong L; Yu X; Wang S; Chen L; Wu Y
Breast Cancer (Dove Med Press); 2023; 15():647-658. PubMed ID: 37644916
[TBL] [Abstract][Full Text] [Related]
11. Triple-Negative Breast Cancer: Breast Tumors With an Identity Crisis.
Nunnery SE; Mayer IA; Balko JM
Cancer J; 2021 Jan-Feb 01; 27(1):2-7. PubMed ID: 33475287
[TBL] [Abstract][Full Text] [Related]
12. Targeting triple-negative breast cancer: A clinical perspective.
Popovic LS; Matovina-Brko G; Popovic M; Punie K; Cvetanovic A; Lambertini M
Oncol Res; 2023; 31(3):221-238. PubMed ID: 37305385
[TBL] [Abstract][Full Text] [Related]
13. Advances in Therapeutic Approaches for Triple-Negative Breast Cancer.
Mahtani R; Kittaneh M; Kalinsky K; Mamounas E; Badve S; Vogel C; Lower E; Schwartzberg L; Pegram M;
Clin Breast Cancer; 2021 Oct; 21(5):383-390. PubMed ID: 33781662
[TBL] [Abstract][Full Text] [Related]
14. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
Lehmann BD; Jovanović B; Chen X; Estrada MV; Johnson KN; Shyr Y; Moses HL; Sanders ME; Pietenpol JA
PLoS One; 2016; 11(6):e0157368. PubMed ID: 27310713
[TBL] [Abstract][Full Text] [Related]
15. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.
Zhao S; Ma D; Xiao Y; Li XM; Ma JL; Zhang H; Xu XL; Lv H; Jiang WH; Yang WT; Jiang YZ; Zhang QY; Shao ZM
Oncologist; 2020 Oct; 25(10):e1481-e1491. PubMed ID: 32406563
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in targeted strategies for triple-negative breast cancer.
Zhu S; Wu Y; Song B; Yi M; Yan Y; Mei Q; Wu K
J Hematol Oncol; 2023 Aug; 16(1):100. PubMed ID: 37641116
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy.
Yang R; Li Y; Wang H; Qin T; Yin X; Ma X
Mol Biomed; 2022 Mar; 3(1):8. PubMed ID: 35243562
[TBL] [Abstract][Full Text] [Related]
18. The evolving management of metastatic triple negative breast cancer.
Malhotra MK; Emens LA
Semin Oncol; 2020 Aug; 47(4):229-237. PubMed ID: 32563561
[TBL] [Abstract][Full Text] [Related]
19. Retrospective study of transcriptomic profiling identifies Thai triple-negative breast cancer patients who may benefit from immune checkpoint and PARP inhibitors.
Suntiparpluacha M; Chanthercrob J; Sa-Nguanraksa D; Sitthikornpaiboon J; Chaiboonchoe A; Kueanjinda P; Jinawath N; Sampattavanich S
PeerJ; 2023; 11():e15350. PubMed ID: 37334114
[TBL] [Abstract][Full Text] [Related]
20. Transcriptomic Analysis of Subtype-Specific Tyrosine Kinases as Triple Negative Breast Cancer Biomarkers.
Limsakul P; Choochuen P; Charupanit G; Charupanit K
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
